There are a total of 12,611 establishments called enemy property, roughly estimated to be worth over Rs 1 lakh crore, in the country.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
World Health Organisation (WHO) chief Tedros Adhanom Ghebreyesus on Wednesday thanked Union Health Minister Mansukh Mandaviya for announcing resumption of COVID-19 vaccine shipments to the COVAX global pool in October.
India will resume export of surplus COVID-19 vaccines next month under the 'Vaccine Maitri' programme and to meet its commitment to the COVAX global pool, but vaccinating its own citizens remains the topmost priority of the government, health minister Mansukh Mandaviya said.
By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.
The trial began at the Kaiser Permanente Washington Health Research Institute in Seattle as the first participant received the investigational vaccine.
The UNICEF is the world's largest single vaccine buyer, procuring more than 2 billion doses of various vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries.
Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
As India launches the world's most ambitious and biggest vaccination drive against COVID-19, the country will encounter the formidable challenge of rapidly scaling up distribution of the vaccines to secure immunity for its entire population, two prominent Indian scientists at World Health Organisation have said.
The 'terrible' surge of the coronavirus cases in India has severely impacted COVAX's vaccine supply in the second quarter of this year to the extent that there will be a shortfall of 190 million doses by the end of June, according to a joint statement by the WHO, UNICEF, GAVI and CEPI.
Coal India achieved a staggering production of 536.51 million tonnes during the financial year ended March 31, 2016
This week, global drugmakers Pfizer and BioNTech said their COVID-19 vaccine candidate is 95 per cent effective, including in adults over 65 years of age.
Nobel laureate Peter Doherty says his 'big worry' is there could be refusals for other vaccines if doubts over its safety turn out to be true.
Microsoft co-founder Bill Gates, whose foundation has been part of the effort to develop and deliver COVID-19 vaccines, has warned that the next four to six months could be the worst of the coronavirus pandemic.
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
So far the coronavirus, which originated in the Chinese city of Wuhan, has infected more than 54 million people around the world and killed over 1.3 million others.
India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the United States company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center.
A chunk of divestment till now has come from follow-on offerings in the Centre's two ETFs, Bharat-22 and CPSE. Now, there will be initial public offerings of Mazagon Docks, rail companies RVNL and IRFC and MSTC.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances